Short Bowel Syndrome Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2019-2026

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Short Bowel Syndrome

4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Global Short Bowel Syndrome Analysis and Forecasts, 2017–2026
4.3.3. Market Revenue Projections (US$ Mn)
4.4. Porter’s Five Force Analysis
4.5. Value Chain Analysis
4.6. Market Outlook
4.7. Disease Overview
4.8. Disease Epidemiology
4.9. Patent Information
4.10. Overview of Clinical Trials
4.11. Qualitative Analysis of GLP-2 product
4.12. Mode of action of SBS drugs
4.13. Regulatory Scenario

5. Global Short Bowel Syndrome Analysis and Forecasts, By Drug Class
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value (US$ Mn) Forecast By Drug Class, 2017–2026
5.4.1. GLP-2
5.4.2. Growth Hormone
5.4.3. Glutamine
5.4.4. Others
5.5. Market Attractiveness by Drug Class

6. Global Short Bowel Syndrome Analysis and Forecasts, By Region
6.1. Key Findings
6.2. Market Value (US$ Mn) Forecast By Region
6.2.1. North America
6.2.2. Europe
6.2.3. Rest of the World
6.3. Market Attractiveness by Country/Region

7. North America Short Bowel Syndrome Analysis and Forecast
7.1. Introduction
7.1.1. Key Findings
7.1.2. Key Trends
7.2. Market Value (US$ Mn) Forecast By Drug Class, 2017–2026
7.2.1. GLP-2
7.2.2. Growth Hormone
7.2.3. Glutamine
7.2.4. Others
7.3. Market Value (US$ Mn) Forecast By Country, 2017–2026
7.3.1. U.S.
7.3.2. Canada
7.3. Market Attractiveness Analysis
7.3.1. By Drug Class
7.3.2. By Country

8. Europe Short Bowel Syndrome Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.1.2. Key Trends
8.2. Market Value (US$ Mn) Forecast By Drug Class, 2017–2026
8.2.1. GLP-2
8.2.2. Growth Hormone
8.2.3. Glutamine
8.2.4. Others
8.3. Market Value (US$ Mn) Forecast By Country, 2017–2026
8.3.1. U.K.
8.3.2. Germany
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe
8.4. Market Attractiveness Analysis
8.4.1. By Drug Class
8.4.2. By Country

9. Rest of the World Short Bowel Syndrome Analysis and Forecast
9.1. Introduction
9.2. Market Value (US$ Mn) Forecast By Drug Class, 2017–2026
9.3. Regional Insights
9.3.1. Japan
9.3.2. India
9.3.3. Australia/New Zealand
9.3.4. China
9.3.5. Middle East
9.3.6. Brazil

10. Competition Landscape
10.1. Market Player – Competition Matrix (By Tier and Size of companies)
10.2. Market Share Analysis by Company (2015)
10.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
10.3.1. Ardelyx, Inc.
10.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.1.2. Business Overview
10.3.1.3. Product Portfolio
10.3.1.4. Financial Overview
10.3.1.5. SWOT Analysis
10.3.1.6. Strategic overview
10.3.2. Emmaus Life Sciences, Inc.
10.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.2.2. Business Overview
10.3.2.3. Product Portfolio
10.3.2.4. Financial Overview
10.3.2.5. SWOT Analysis
10.3.2.6. Strategic overview
10.3.3. GLyPharma Therapeutic, Inc.
10.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.3.2. Business Overview
10.3.3.3. Product Portfolio
10.3.3.4. Financial Overview
10.3.3.5. SWOT Analysis
10.3.3.6. Strategic overview
10.3.4. Merck KGaA
10.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.4.2. Business Overview
10.3.4.3. Product Portfolio
10.3.4.4. Financial Overview
10.3.4.5. SWOT Analysis
10.3.4.6. Strategic overview
10.3.5. Naia Pharmaceuticals, Inc.
10.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.5.2. Business Overview
10.3.5.3. Product Portfolio
10.3.5.4. Financial Overview
10.3.5.5. SWOT Analysis
10.3.5.6. Strategic overview
10.3.6. Nutrinia Ltd.
10.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.6.2. Business Overview
10.3.6.3. Product Portfolio
10.3.6.4. Financial Overview
10.3.6.5. SWOT Analysis
10.3.6.6. Strategic overview
10.3.7. OxThera
10.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.7.2. Business Overview
10.3.7.3. Product Portfolio
10.3.7.4. Financial Overview
10.3.7.5. SWOT Analysis
10.3.7.6. Strategic overview
10.3.8. Sancilio & Company, Inc.
10.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.8.2. Business Overview
10.3.8.3. Product Portfolio
10.3.8.4. Financial Overview
10.3.8.5. SWOT Analysis
10.3.8.6. Strategic overview
10.3.9. Shire plc
10.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.9.2. Business Overview
10.3.9.3. Product Portfolio
10.3.9.4. Financial Overview
10.3.9.5. SWOT Analysis
10.3.9.6. Strategic overview
10.3.10. Zealand Pharma A/S
10.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.10.2. Business Overview
10.3.10.3. Product Portfolio
10.3.10.4. Financial Overview
10.3.10.5. SWOT Analysis
10.3.10.6. Strategic overview